Extracorporeal CO2 Removal Devices Market Size & Growth Forecast 2027–2036, By Segments (Product, Application, End-use, Access), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Extracorporeal CO2 Removal Devices Market size was valued at USD 103 million in 2026 and is anticipated to grow at a 7.03% CAGR from 2027 to 2036, attaining USD 203.19 million by 2036. The industry revenue for 2027 is calculated at USD 109.1 million.
Get more details on this report
Request Free Sample ReportExtracorporeal CO2 Removal Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to advanced critical care infrastructure, high ICU capacity, and widespread availability of extracorporeal support technologies in hospitals.
- Europe growth is driven by increasing adoption of less invasive respiratory support strategies and expanding ICU capabilities, supported by an 8.25% CAGR.
Segment Momentum
- Extracorporeal CO2 Machines held a 55.02% share in 2026 because they serve as the core treatment platform, determining system functionality, workflow integration, monitoring, and overall clinical delivery.
- Acute Respiratory Distress Syndrome (ARDS) is the fastest-growing application, driven by increasing use of advanced respiratory support in intensive care settings where conventional ventilation may be insufficient.
Market Expansion Drivers
- Rising COPD and ARDS cases increasing demand for extracorporeal CO2 removal devices.
- Advancements in ECMO-compatible membrane oxygenators improving ICU respiratory support efficiency.
- Expanding use in lung transplantation and thoracic surgeries enhancing perioperative outcomes.
Leading Market Participants
- Major players in the extracorporeal CO2 removal devices market include Medtronic plc (Ireland), Getinge AB (Sweden), Xenios AG (Germany), Medica S.p.A. (Italy), Aferetica srl (Italy), ESTOR S.P.A. (Italy), Baxter International Inc. (United States), X-COR Therapeutics (United States), Fresenius Medical Care AG & Co. KGaA (Germany).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 103 million
- 2027 Estimated Market Size: USD 109.1 million.
- Projected Market Size: USD 203.19 million by 2036
- Growth Forecast: 7.03% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Europe
- Core Revenue Segment: Extracorporeal CO2 Machines (Product) | Bridge to Lung Transplant (Application) | Hospitals (End-use) | Venovenous (Access)
- Emerging Opportunity Segment: Disposables (Product) | Acute Respiratory Distress Syndrome (ARDS) (Application) | Hospitals (End-use) | Arteriovenous (Access)
Market Growth Drivers and Industry Trends
Rising COPD and ARDS cases increasing demand for extracorporeal CO2 removal devices
The increasing clinical burden of COPD and ARDS will drive the extracorporeal CO2 removal devices market by creating greater demand for advanced respiratory support when conventional ventilation is insufficient or difficult to tolerate. Patients with severe respiratory impairment can experience significant carbon dioxide retention, creating a need for technologies capable of removing excess CO2 from the bloodstream while supporting lung-protective treatment strategies. Growing recognition of severe respiratory failure and the need to reduce ventilator-related stress are encouraging critical care specialists to consider extracorporeal approaches in appropriate patients. Greater clinical experience with advanced respiratory support is also strengthening interest in these devices within intensive care settings.
Advancements in ECMO-compatible membrane oxygenators improving ICU respiratory support efficiency
Technological advances in membrane oxygenators compatible with ECMO systems will propel the extracorporeal CO2 removal devices market by improving the integration of CO2 removal capabilities into established extracorporeal respiratory support infrastructure. Improvements in membrane performance, blood compatibility, flow management, and circuit design can support more efficient gas exchange while helping clinicians manage complex respiratory failure cases. Compatibility with ECMO-based systems can also facilitate the use of extracorporeal support within intensive care environments that already have specialized equipment and trained personnel. These developments broaden the clinical utility of extracorporeal CO2 removal approaches for patients requiring carefully controlled respiratory assistance.
Expanding use in lung transplantation and thoracic surgeries enhancing perioperative outcomes
Growing application of extracorporeal CO2 removal in lung transplantation and thoracic surgery will boost the extracorporeal CO2 removal devices market by providing clinicians with an additional method for managing gas exchange during complex procedures and postoperative recovery. Patients undergoing major thoracic interventions can face substantial respiratory challenges before, during, and after surgery, particularly when lung function is compromised. Extracorporeal support can assist with CO2 management while allowing clinical teams to address surgical requirements and postoperative respiratory instability. Increasing use of advanced perioperative support techniques is therefore expanding the relevance of extracorporeal CO2 removal beyond conventional intensive care applications.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising COPD and ARDS cases increasing demand for extracorporeal CO2 removal devices | 2.10% | High | North America, Europe | Emerging | Near Term |
| Advancements in ECMO-compatible membrane oxygenators improving ICU respiratory support efficiency | 1.70% | High | North America, Europe | Medium | Mid Term |
| Expanding use in lung transplantation and thoracic surgeries enhancing perioperative outcomes | 1.50% | High | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the extracorporeal CO2 removal devices market in 2026, reflecting advanced critical-care infrastructure, high adoption of sophisticated respiratory support technologies, and strong clinical capabilities for managing severe respiratory conditions. The region's established healthcare systems facilitate the integration of extracorporeal therapies into specialized intensive care settings, while continued clinical research is supporting greater understanding of CO2 removal approaches. Demand is also reinforced by increasing attention to advanced lung-support strategies and the availability of specialized medical facilities capable of administering complex extracorporeal treatments. Ongoing technological development and clinician familiarity with advanced respiratory support are expected to sustain the region's leading position.
Europe (Fastest-Growing Region)
Europe is the fastest-growing region, supported by expanding interest in advanced respiratory therapies, improving critical-care capabilities, and increasing clinical adoption of extracorporeal approaches for selected patients. Greater emphasis on improving outcomes for individuals with severe respiratory failure is encouraging healthcare providers to evaluate complementary technologies that can reduce carbon dioxide levels while supporting lung-protective treatment strategies. Investments in hospital infrastructure, clinical research, and specialized intensive-care services are also contributing to market development. Furthermore, growing awareness among healthcare professionals and progress in device design are helping improve the accessibility and clinical applicability of extracorporeal CO2 removal technologies across European healthcare systems.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Hospital-Based Clinical AdoptionGermany is integrating extracorporeal CO2 removal devices into specialized intensive care settings where respiratory management protocols continue to evolve. Healthcare providers are assessing device performance alongside established extracorporeal treatment pathways.
France 🇫🇷
Evidence-Driven Clinical UseFrance is emphasizing clinically validated extracorporeal CO2 removal technologies for carefully selected respiratory care applications. Healthcare institutions are prioritizing devices that demonstrate practical integration with established intensive care practices.
Italy 🇮🇹
Specialized Critical Care AccessItaly is expanding access to extracorporeal CO2 removal devices through specialized hospitals treating patients with complex respiratory conditions. Clinical priorities include effective integration into critical care pathways while supporting consistent treatment outcomes.
Japan 🇯🇵
Precision Respiratory CareJapan is exploring extracorporeal CO2 removal devices to strengthen advanced respiratory care in hospitals managing complex pulmonary conditions. Clinical attention is focused on technologies that support effective carbon dioxide removal with careful patient monitoring.
South Korea 🇰🇷
Advanced ICU IntegrationSouth Korea is incorporating extracorporeal CO2 removal devices into modern intensive care environments supported by expanding critical care capabilities. Hospitals are evaluating systems that complement existing respiratory treatment approaches and improve clinical workflow.
United States 🇺🇸
Critical Care InnovationThe U.S. extracorporeal CO2 removal devices market is supported by advanced critical care facilities evaluating less invasive respiratory support technologies. Clinical adoption is driven by interest in expanding treatment options for patients with severe respiratory complications.
Segment Leadership and Growth Trends
Extracorporeal CO2 Removal Devices Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Extracorporeal CO2 Machines (Largest Segment) vs Disposables (Fastest-Growing Segment)
Extracorporeal CO2 machines led the extracorporeal CO2 removal devices market with a 55.02% share in 2026, reflecting their central role in extracorporeal respiratory support and carbon dioxide removal procedures. These systems provide the primary technological platform for managing extracorporeal gas exchange, making them essential for complex respiratory care applications. Increasing clinical interest in advanced respiratory support, particularly for patients who require assistance beyond conventional ventilation strategies, is supporting demand for sophisticated CO2 removal systems. Improvements in device performance, monitoring capabilities, and treatment integration are further strengthening their clinical relevance.
Disposables are expected to be the fastest-growing product segment, driven by their essential role in maintaining treatment safety, hygiene, and procedural reliability. Consumable components must be replaced between treatments or according to clinical protocols, creating recurring demand alongside the installation and use of extracorporeal CO2 removal systems. Greater adoption of extracorporeal therapies is consequently expanding the requirement for compatible circuits, filters, membranes, and other disposable components, while healthcare providers' focus on infection control and operational efficiency further supports segment growth.
Application Segment Analysis: Bridge to Lung Transplant (Largest Segment) vs Acute Respiratory Distress Syndrome (ARDS) (Fastest-Growing Segment)
The bridge to lung transplant application accounted for the largest share of 41.98% in 2026, supported by the role of extracorporeal CO2 removal in stabilizing critically ill patients who require advanced respiratory support while awaiting transplantation. These technologies can help manage severe respiratory insufficiency and potentially support patients through periods when conventional approaches are inadequate. Growing use of advanced extracorporeal support in specialized transplant centers and the need for carefully managed pathways for critically ill candidates are contributing to the segment's leading position.
Acute respiratory distress syndrome (ARDS) is projected to be the fastest-growing application, driven by increasing clinical interest in extracorporeal strategies for managing severe respiratory failure. CO2 removal technologies can complement respiratory support by reducing carbon dioxide burden and potentially allowing clinicians to pursue more protective ventilation strategies. Continued advances in critical care, greater awareness of extracorporeal treatment options, and the need for alternative approaches in severe respiratory cases are supporting broader consideration of these devices in ARDS management.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Extracorporeal CO2 Machines, Disposables, Others | Extracorporeal CO2 Machines | Disposables |
| Application | Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Bridge to Lung Transplant, Others | Bridge to Lung Transplant | Acute Respiratory Distress Syndrome (ARDS) |
| End-use | Hospitals, Ambulatory Surgical Centers, Clinics, Others | Hospitals | Hospitals |
| Access | Venovenous, Arteriovenous | Venovenous | Arteriovenous |
Competitive Landscape and Market Positioning
Prominent players in the extracorporeal CO2 removal devices market:
1. Medtronic plc (Ireland)
2. Getinge AB (Sweden)
3. Xenios AG (Germany)
4. Medica S.p.A. (Italy)
5. Aferetica srl (Italy)
6. ESTOR S.P.A. (Italy)
7. Baxter International Inc. (United States)
8. X-COR Therapeutics (United States)
9. Fresenius Medical Care AG & Co. KGaA (Germany)
The extracorporeal CO2 removal devices market is witnessing continuous innovation focused on compact system design, improved patient safety, and enhanced respiratory support efficiency. Investments in advanced membrane technologies and minimally invasive solutions are strengthening product differentiation while supporting broader clinical adoption in critical care settings.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Medtronic plc (Ireland) | |||||||
| Getinge AB (Sweden) | |||||||
| Xenios AG (Germany) | |||||||
| Medica S.p.A. (Italy) | |||||||
| Aferetica srl (Italy) | |||||||
| ESTOR S.P.A. (Italy) | |||||||
| Baxter International Inc. (United States) | |||||||
| X-COR Therapeutics (United States) | |||||||
| Fresenius Medical Care AG & Co. KGaA (Germany). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| ALung Technologies | Oct-22 | ALung Technologies initiated clinical evaluations of its Hemolung Respiratory Assist System to assess its efficacy in delivering low-flow extracorporeal CO2 removal for patients experiencing acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). This study aims to demonstrate the utility of the device in reducing reliance on traditional invasive mechanical ventilation. |
| LivaNova PLC | May-22 | LivaNova PLC acquired ALung Technologies to integrate the Hemolung Respiratory Assist System into its clinical portfolio. This acquisition strengthens LivaNova’s position in the respiratory care segment by providing access to advanced extracorporeal CO2 removal technology, designed to serve as a viable alternative or adjunct to invasive mechanical ventilation. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Extracorporeal CO2 Removal Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Purchasing Model | Capital Equipment Purchase, Procedure-Based Purchase, Rental & Leasing, Managed Equipment Agreements |
| Reimbursement Coverage | Fully Reimbursed, Partially Reimbursed, Coverage Under Case-Based Payment, Self-Pay & Unreimbursed |
| Patient Age Group | Neonatal & Pediatric, Adult, Geriatric |
Extracorporeal CO2 Removal Devices Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Critical Care Treatment Pathway Assessment |
|
| Clinical Adoption Barrier Assessment |
|
| Healthcare Infrastructure Readiness Analysis |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of extracorporeal CO2 removal devices?
How is the extracorporeal CO2 removal devices industry expected to grow over the next 10 years?
How are advances in ECMO-compatible technologies supporting adoption of extracorporeal CO2 removal devices?
Which clinical settings are creating new demand opportunities for extracorporeal CO2 removal devices?
Why are Extracorporeal CO2 Machines the leading product segment?
Which application segment is growing fastest in the extracorporeal CO2 removal devices market?
Why does North America lead extracorporeal CO2 removal devices market?
How is Europe driving growth in extracorporeal CO2 removal devices market?
Which organizations are considered leaders in the extracorporeal CO2 removal devices landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization